Lilly recruits top Swedish researcher in Alzheimer´s
Av Oskar Hansson, a professor of neurology at Lund University, will hold the title of Vice President for Neurodegenerative Disease Early Phase Clinical and Imaging Development at the American pharmaceutical company.
He is to work in the field of neurodegenerative diseases and develop biomarkers for conditions such as Alzheimer's disease, Parkinson's disease, and ALS. Initially, he will be based in Sweden before moving to one of Eli Lilly's offices in the USA.
"I am incredibly happy to join Lilly at such a crucial time for the company. Sweden is a world leader in Alzheimer's research, and I look forward to using my experience to further strengthen the collaboration between Lilly and our local and global stakeholders to improve the lives of people affected by Alzheimer's disease," said Oskar Hansson in a press release.
Oskar Hansson is an internationally recognized and multiple award-winning researcher in his field with over 500 published original articles and more than 60,000 citations. He is a professor of neurology and head of a research group at the Clinical Memory Research Unit at Lund University. He has also held medical positions at Skåne University Hospital and Washington University in St. Louis.
"Oskar's extensive experience and innovative mindset will be invaluable in achieving our goal of improving the lives of patients with various neurodegenerative diseases," said Daniel Lucas, Vice President and General Manager for the Nordic region of Eli Lilly, in a comment.
Eli Lilly is currently growing rapidly, not least thanks to its successes in diabetes and weight loss medications. However, the company is also at the forefront of neurodegenerative diseases and earlier this year received approval in the USA for its drug donanemab as a treatment for Alzheimer's disease. It became the second approved disease-modifying drug for the disease, alongside lecanemab, which was developed by Swedish Bioarctic together with Eisai.
Donanemab is currently under evaluation by the European Medicines Agency (EMA).
Artikeln är en del av vårt tema om News in English.